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Abstract35
36
Background: One in three hospital acute medical admissions is of an older person with cognitive37
impairment. Their outcomes are poor and the quality of their care in hospital has been criticised. A38
specialist unit to care for older people with delirium and dementia (the Medical and Mental Health39
Unit, MMHU) was developed and then tested in a randomised controlled trial where it delivered40
significantly higher quality of, and satisfaction with, care, but no significant benefits in terms of41
health status outcomes at three months.42
43
Objective: To examine the cost-effectiveness of the MMHU for older people with delirium and44
dementia in general hospitals, compared with standard care.45
46
Methods: Six hundred participants aged over 65 admitted for acute medical care, identified on47
admission as cognitively impaired, were randomised to the MMHU or to standard care on acute48
geriatric or general medical wards. Cost per quality adjusted life year (QALY) gained, at 3-month49
follow-up, was assessed in trial-based economic evaluation (599/600 participants, intervention:50
309). Multiple imputation and complete-case sample analyses were employed to deal with missing51
QALY data (55%).52
53
Results: The total adjusted health and social care costs, including direct costs of the intervention, at54
3 months was £7714 and £7862 for MMHU and standard care groups, respectively (difference -£14955
(95% confidence interval [CI]: -298, 4)). The difference in QALYs gained was 0.001 (95% CI: -0.006,56
0.008). The probability that the intervention was dominant was 58%, and the probability that it was57
cost-saving with QALY loss was 39%. At £20,000/QALY threshold, the probability of cost-58
effectiveness was 94%, falling to 59% when cost-saving QALY loss cases were excluded.59
60
Conclusions: The MMHU was strongly cost-effective using usual criteria, although considerably less61
so when the less acceptable situation with QALY loss and cost savings were excluded. Nevertheless,62
this model of care is worthy of further evaluation.63
64
65
Trial Registration: ClinicalTrials.gov, NCT01136148,https://clinicaltrials.gov/ct2/show/NCT0113614866
67
Funding: National Institute for Health Research, UK.68
69
Keywords: Delirium, dementia, cognitive impairment, aged, emergency care, general hospitals,70
randomised controlled trial, cost-effectiveness analysis.71
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Introduction76
77
Background78
79
About 50% of people over the age of 65 in general hospitals have delirium, dementia or both,80
representing one in three hospital acute medical admissions. [1-3] Various models have been81
proposed to provide for their particular needs. [3-5] The National Dementia Strategy for England82
promotes old age liaison psychiatry services, [4] although it is unclear of what such services should83
comprise, how they facilitate high quality care, and there is no firm evidence of their cost-84
effectiveness. [5] We developed an alternative model - a specialist unit in a general hospital to care85
for people with delirium and dementia (the Medical and Mental Health Unit (MMHU)). [6] Its86
development aimed to reflect best practice in dementia and delirium care taking into account the87
published literature, [6 7] [8] and expert opinion from clinicians working in the field. It was tested in88
a randomised controlled trial (Trial of an Elderly Acute care Medical and mental health unit (TEAM)),89
[7 8] which showed that the quality of care was higher, as judged by direct observation and carer90
satisfaction, but benefits in health status outcomes at three months were small and not statistically91
significant [8]. There are no other robust studies of these types of specialist units and the cost and92
economic implications of this model of care are not yet known.93
94
This analysis compared the costs and cost-effectiveness of the MMHU with those of standard care,95
from the perspective of the National Health Service and publically funded personal social care. The96
trial-based economic evaluation is reported in accordance with the CHEERS Statement (Appendix97
S1).98
99
100
Medical and Mental Health Unit and standard care wards101
102
An existing 28-bed acute geriatric medical ward, including its ward-based staff, was converted to a103
specialist unit, MMHU, where only older patients with cognitive impairment were admitted. Five104
main areas of enhancement (described in depth elsewhere [6]) were: 1) Additional specialist mental105
health staff were employed (mental health nurses and occupational therapist along with additional106
support from physiotherapy, speech and language therapy, psychiatry and geriatric medicine),107
including three healthcare assistants working as activity coordinators; 2) Staff training in recognition108
and management of delirium and dementia and the delivery of person-centred dementia care;109
3) A programme of organised therapeutic and diversionary activities; 4) The environment was made110
more appropriate for people with cognitive impairment; 5) A proactive and inclusive approach to111
family carers was promoted.112
113
Standard care wards included five acute geriatric medical wards, and six general (internal) medical114
wards. Practice on geriatric medical wards was based on the principles of comprehensive geriatric115
assessment, [9] and staff had general experience in the management of delirium and dementia.116
Mental health support was provided, on request, from visiting psychiatrists. There was no dedicated117
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old age liaison psychiatry service at that time. None of the MMHU enhancements listed and118
described above was routine on standard care wards.119
120
121
TEAM trial122
123
A randomised controlled trial, Trial of an Elderly Acute care Medical and mental health unit (TEAM),124
was conducted. [8] The trial protocol (Protocol S1) was published, [7] and the full report on the trial,125
including recruitment flow chart, is available elsewhere as an open-access article.[8]126
127
Patients were recruited who had been admitted for acute medical care to a single large teaching128
hospital. Participants were aged over 65, and identified by admissions unit physicians as being129
‘confused’. We used the term ’confused’ as there is considerable overlap between delirium and130
dementia in this population, [3] and dementia is often undiagnosed in the community and hospital.131
[3 10] Suitable patients identified on the hospital’s medical admissions unit were entered onto a132
computerised screening log and, if a bed was available on the MMHU, randomised 1:1 between the133
MMHU and standard care in a permuted block design, stratified for previous care home residence.134
Randomised patients who were readmitted were assigned their original allocation. Regardless of135
allocation, patients had access to standard medical and mental health services, rehabilitation,136
intermediate and social care. Baseline clinical data was collected from the patient, family members,137
or other informal or professional carers by interview with a researcher. Outcomes were ascertained138
at interviews at home 90 days (±7 days) after randomisation by researchers not involved in139
recruitment or baseline data collection, and blind to allocation.140
141
Between July 2010 and December 2011, 310 patients were recruited from the MMHU and 290 from142
standard care. One patient in the MMHU arm was lost to follow-up (moved away from the143
geographical area). A professional consultee was involved in the recruitment of 30 MMHU and 31144
standard care participants, as allowed by English mental capacity law when a patient lacking mental145
capacity has no family or friends to advocate for them. Baseline characteristics of the population and146
clinical effectiveness outcomes have been reported previously. [8] In short, there was no statistically147
significant difference between settings in the trial primary outcome, days spent at home (median 51148
vs 45 days; 95% confidence interval [CI] for difference -12 to 24; p = 0.3); median index hospital stay149
was 11 vs 11 days, mortality 22% vs 25% (95% CI for difference: -9%, 4%), readmission 32% vs 35%150
(95% CI for difference: -10%, 5%), and new care home admission 20% vs 28% (95% CI for difference:151
-16%, 0), for the MMHU and standard care, respectively. Participants on the MMHU spent152
significantly more time with positive mood or engagement (79% vs 68%; 95% CI for difference: 2%,153
20%; p = 0.03), and experienced more staff interactions that addressed emotional and psychological154
needs (median 4 vs 1 per observation; p<0.001). More family carers were satisfied with care (overall155
91% vs 83%; 95% CI for difference: 2%, 15%; p = 0.004), and severe dissatisfaction was reduced (5%156
vs 10%; 95% CI for difference: -10%, 0; p = 0.05). [8]157
158
159
Methods160
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Health effects161
162
The health outcome for the cost-effectiveness analysis was quality-adjusted life year (QALY) gained,163
constructing utility values from the 3-level EuroQol-5D (EQ-5D-3L) [11] with societal weights. [12]164
We used EQ-5D utility measure in this economic evaluation because of its relevance for UK policy165
makers, particularly the National Institute for Health and Care Excellence (NICE). [13] Patient-166
reported EQ-5D valuations at baseline and 90-day follow up (measuring health state on a scale in167
which 0 and 1 represent death and full health, respectively) were applied to estimate QALYs gained,168
assuming baseline utility until date of death for a patient dead at follow up. Hence, a patient’s QALYs169
gained were calculated as the area under curve using linear interpolation between EQ-5D170
measurement points, and health outcome was summarised into a single index. Due to the nature of171
the population studied, 55% of participants had missing data for self-reported EQ-5D. Other health172
status variables [8] were used to impute values in these cases, including proxy completed EQ-5D,173
dementia-related quality-of-life at follow up (DEMQOL [14]), behavioural and psychological174
symptoms (Neuro-Psychiatric Inventory (NPI) [15]), and dependency in personal activities of daily175
living (Barthel ADL [16]).176
177
178
Costs179
180
Costs of delivering the MMHU intervention181
182
The MMHU intervention cost was calculated as the additional MMHU staffing cost compared with183
standard care on a general or geriatric ward – additional staff employed on MMHU and associated184
costs are presented in Table 1. Staff salary levels were based on salary levels from NHS pay scales185
2011/12. [17] In order to estimate the cost of staff involved in direct patient care, as opposed to186
other activities such as general management and training, salary costs were adjusted by the187
proportion of time spent on patient care on the ward. For instance, the occupational therapist,188
mental health nurse and consultant spent two-thirds of their time on direct patient care so their189
total annual cost was multiplied by 0.67. The total additional staffing cost was allocated on an190
individual patient basis (for patients recruited to the MMHU arm of the trial), assuming 100% bed191
occupancy on MMHU (28 beds), by multiplying the per-bed-day additional MMHU cost by the192
individual patient’s length of stay on MMHU – calculations are presented in Table 1.193
194
195
196
197
198
199
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200
201
Health and social care resource-use data202
203
Most health and social care services now use electronic administrative record systems to record204
patient care. [18] Approvals were gained to obtain electronic administrative record systems data205
from hospitals, social care, general practices (GP), ambulance services, and mental healthcare. Data206
were collected for three months post-hospital admission and one year pre-admission (July 2009 –207
March 2012). Based on our previous research, [18] extensive fieldwork was completed with the208
included agencies to derive parameters covering resource-use (details in Appendix S2).209
210
Hospital care data (day-case, inpatient, outpatient and intensive care) were obtained from two211
patient administration systems for patients that attended five hospitals in the Nottingham area.212
Primary care resource-use data were obtained from Nottingham City and Nottinghamshire County213
GP practices. Of 107 GP practices serving our cohort, data were obtained from 72 practices (468/599214
participants), coming from five electronic administrative record systems: SystmOne, 220 (47%); EMIS215
LV, 196 (42%); EMIS Web, 34 (7%); Synergy, 13 (3%); and EMIS PCS, 5 (1%), and were anonymised at216
the GP practice. Ambulance service resource-use was extracted from the Caller Aided Despatch217
(CAD) IT service. The CAD system was cross-referenced with paper-based Patient Record Forms to218
identify participants (using participant name and place of pick-up). Data from mental healthcare219
services for older people were provided by the Nottinghamshire Healthcare Trust data via the RiO220
Table 1. Derivation of MMHU intervention cost
Category
(NHS salary band)
N
Annual
salary (£)a
On-costs
(£)b
Total annual
cost (£)
Ward time
adjustmentc
Adjusted total
annual cost (£)c
Occupational therapist (band 7) 1 35184 8268 43452 0.67 spent on ward 29113
Healthcare assistant (band 2) 2 30473 6625 37098 100% on ward 37098
Mental health nurse (band 7) 1 35184 8898 44082 0.67 spent on ward 29535
Mental health nurse (band 5) 2 48143 11618 59761 100% on ward 59761
Speech and language therapist (band 6) 0.1 2946 692 3639 100% on ward 3639
Activity coordinator (band 2) 3 45710 9937 55646 100% on ward 55646
Consultant (MC58) 0.3 26811 7226 34037 0.67 spent on ward 22805
Physiotherapy (band 6) 0.5 14732 3462 18194 100% on ward 18194
Total annual MMHU additional cost 295909 £255791
Additional cost per-dayd £700
Additional cost per-bed-daye £25
Mean per-patient intervention cost
(full-sample)f
£368
(95% CI: 334, 410)
NB: all figures presented are rounded to 0 decimal places.
aAnnual salary based on proportion of time employed for working on MMHU; annual staffing and salary information from ward proposal,
based on 2011/12 FY NHS pay scales mid-point salary levels; consultant salary was based on threshold 6 of pay scale MC58 for 2011/12 FY.
bSalary on-costs taken from PSSRU 2011/12.
cTotal cost adjusted based on time spent on the MMHU during the trial period – time spent by professional on training staff and
management not included in ward time adjustment.
dCalculated as: £255790.55/365.25 = £700.32
eCalculated, assuming 100% occupancy (28 beds), as: £700.32/28 = £25.01
fCalculated as mean per-patient MMHU additional cost for participants recruited to the MMHU arm of the trial (309 patients in the full
sample CEA), for whom mean length of stay on MMHU was 14.73 days (95% confidence interval [CI]: 13.35, 16.37): £25.01∙14.73 = 
£368.45. MMHU intervention cost is calculated on an individual patient basis, by multiplying per-bed-day MMHU additional cost (£25.01)
by the patient’s length of stay on MMHU. Mean per-patient intervention costs for the complete-case CEA dataset is presented in Table 4.
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system. [19] Social care services within two different catchment areas (City and County), operating221
two different electronic systems, were identified. Services consisted of contacts and assessments,222
and care plans. Care plans included home, day, residential and telecare, housing and meals at home223
services.224
225
226
Patient-level cost227
228
Unit costs for primary care services were applied based on time taken to perform each task using229
time assumptions obtained from PSSRU 2011/12, [17] empirical literature, or expert opinion, and230
mid-point yearly salary estimations taken from the NHS “Agenda for Change” pay rates. [20] Unit231
costs of hospital care were applied using national reference costs according to Healthcare Resource232
Group (HRG) case-mix. Inpatient spell costs were adjusted for length-of-stay using standard excess233
bed day costs. Unit costs for other services were obtained from PSSRU, standard Department of234
Health costs and other reference costs for the 2011/12 financial year. The detailed costing methods235
are described elsewhere, [18] the sources of unit costs are presented in Appendix S2 and the HRG236
codes used to derive costs are presented in Appendix S3. Due to the high number of different237
parameters and unit costs used to calculate patient-level cost (an example of which is provided in238
Appendix S3 for the codes used to assign unit costs to hospital resource-use), only a brief overview239
of the other costs are described below.240
241
Unit costs were combined with resource-use to generate patient-level costs. Patient-level costs from242
all health and social care services incurred during the trial were calculated for all trial participants243
who remained in the study at 90-day follow-up (patients who died during the study were not classed244
as ‘withdrawn’).245
246
247
Cost-effectiveness analysis248
249
The economic evaluation adopted a health and social services perspective. The incremental cost-250
effectiveness ratio (ICER) generated by the MMHU over standard care was calculated using the251
following equation:252
253
,

MMHU SC
MMHU SC
Cost CostICER
QALY QALY
254
255
where CostMMHU (CostSC) and QALYMMHU (QALYSC) are mean cost and QALYs gained in the MMHU256
(standard care) group, respectively. Patient cost and QALYs were adjusted by baseline characteristics257
using regression methods, including one year pre-admission healthcare costs as a covariate when258
modelling costs. Pairwise bootstrapping with replacement was employed for adjusted patient costs259
and QALYs, using 5000 replications. The resultant incremental costs and outcomes were plotted on a260
cost-effectiveness plane. [21] To investigate uncertainty around the ICER, cost-effectiveness261
acceptability curves (CEACs) [22 23] based on ceiling ratios were constructed. These (standard)262
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CEACs represent probability of cost-effectiveness for a given willingness to pay (WTP) for QALY gain,263
equal to willingness to accept (WTA) QALY loss, that is, WTA/WTP ratio equal to 1. [24]264
265
Sensitivity analysis to capture WTA/WTP disparity was conducted. Probability of cost-effectiveness266
for a £20,000 WTP threshold in relation to WTA/WTP ratio was investigated, [24] to account for the267
notion that QALY gains at additional cost (WTP) may be more acceptable for decision makers, when268
compared to cost savings and QALY losses (WTA), as suggested in the health and behavioral269
economics literature. [24-26] Conservatively, WTA/WTP ratio between 1 and infinity [24],270
corresponding to WTA threshold between £20,000 and infinity for accepting QALY loss, respectively271
(SW quadrant of cost-effectiveness plane), was assumed in the sensitivity analysis. Namely, the272
WTA/WTP ratio, r, r ≥ 1, reflected the proportion that, paying £20,000 maximum for QALY gain (NE273
quadrant of cost-effectiveness plane), QALY loss was accepted for minimum r ∙ £20,000 (SW 274
quadrant of cost-effectiveness plane).275
276
The analyses were performed using STATA version 12 [27] and Microsoft Excel 2010.277
278
279
Missing data280
281
In the case of 90-day (trial) cost data, only primary care data were missing (131/599 (21.9%)282
patients). One year pre-admission healthcare cost was missing for inpatient care (2/599 (0.3%)) and283
for primary care (155/599 (25.9%)).284
285
Missing data for patient-reported EQ-5D are: 195/599 (32.6%) baseline EQ-5D, 209/599 (34.9%)286
follow-up EQ-5D, resulting in QALYs obtained for 272/599 (45.4%) patients, including 62 (MMHU: 30)287
dead at follow up.288
289
No statistically significant differences in the proportions of missing EQ-5D and QALYs values between290
MMHU and standard care groups were observed: 92/309 (29.8%) vs. 103/290 (35.5%), p = 0.13, for291
baseline EQ-5D; 113/309 (36.6%) vs 96/290 (33.1%), p = 0.37, for follow-up EQ-5D; and 170/309292
(55.0%) vs 157/290 (54.1%), p = 0.83, for QALYs. Furthermore, for primary care cost and for other293
health measurement variables of interest, the differences in the proportions of missing values294
between arms were non-significant; the percentage of missing values in the two arms was similar295
apart from proxy completed EQ-5D and follow-up Barthel ADL index (see Appendix S4)296
297
Missing values for cost, EQ-5D, and for other variables, were assumed to be missing at random (MAR).298
Given no imbalance in proportions of missing values between randomised groups (as shown above299
and in Appendix S4) and predictors of missing values for EQ-5D (and for other health status variables)300
identified among variables with complete data (age, number of medical conditions, and permanent301
care home residence at baseline - see Appendix S4 for details) the MAR assumption seemed to be302
plausible. Hence, the multiple imputation approach was applied to deal with missing data in cost-303
effectiveness analysis.304
305
Missing values for cost, EQ-5D, and for other variables of interest, were imputed using multiple306
imputation by chained equations (MICE), [28] incorporating the set of variables: age and sex; proxy-307
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EQ-5D, NPI, Barthel ADL score, number of medical conditions - at baseline and follow-up; DEMQOL308
at follow up; as well as primary, inpatient, day-case, and outpatient care (trial and one year pre-309
admission) costs, social care (trial) costs, and permanent care home residence at baseline. To avoid310
bias, all variables included in the models for adjusted costs and QALYs in cost-effectiveness analysis311
were incorporated in the imputation. [28 29] In particular, since we imputed missing values of the312
models covariates, model outcomes (costs and follow-up EQ-5D determining QALYs) were included313
in the imputation model as well. [28 30] Additionally, by having the predictors of missing values for314
EQ-5D (and for other health status variables) in the imputation model (age, number of medical315
conditions, and care home residence at baseline) potential bias was reduced (MAR assumption was316
more plausible) and the standard errors in the adjustment multiply imputed models were317
minimised. [28]318
319
One hundred imputed datasets were generated; based on the rule of thumb that the number of320
imputations was higher than the percentage of patients with at least one variable in the imputation321
model missing, equal to 94% [28] (percentages of missing values are at baseline and follow up,322
respectively: 33% and 56% (proxy EQ-5D), 1% and 15% (Barthel ADL), 53% and 25% (NPI), and 41%323
(DEMQOL, follow-up collected only)).324
325
An alternative approach to deal with missing data, complete-case cost-effectiveness analysis, was326
applied. That is, 209/599 (34.9%) patients with complete QALY and trial cost data (210 patients), for327
whom one-year pre-admission secondary care cost data were also complete, were included in a328
complete-case cost-effectiveness analysis. In this approach, one year pre-admission secondary care329
cost and other covariates with complete data in the sub-sample of 209 patients were considered for330
the models for adjusted cost and QALYs. Due to the choice of adjustment covariates being the331
predictors of missing EQ-5D data at follow up, the MAR assumption was also sufficient to reduce332
bias in cost-effectiveness estimates. Hence, the unadjusted estimates were provided under missing333
completely at random (MCAR) assumption, while the MAR assumption was sufficient to justify334
complete-case adjusted cost-effectiveness analysis (CEA).335
336
337
Full-sample (using imputed values) cost-effectiveness analysis338
339
In the full-sample CEA, imputed missing primary care and EQ-5D data were incorporated into the340
generation of incremental costs and QALYs. Unadjusted costs in MMHU and standard care, as well as341
incremental costs by services were analysed, handling uncertainty by non-parametric bootstrapping.342
[31]343
344
In the adjusted CEA, other variables with imputed missing values (one year pre-admission primary345
care cost, NPI and Barthel ADL score) were also used to adjust cost and QALYs for baseline346
characteristics. Finally, adjusted cost was estimated controlling for age, sex, EQ-5D utility index and347
permanent care home residence at baseline, and one year pre-admission healthcare cost. Adjusted348
QALYs were estimated controlling for age, sex, and baseline EQ-5D utility index, permanent care349
home residence, number of medical conditions, NPI, and Barthel ADL score. The adjustment models350
for both cost and QALYs included age, sex, EQ-5D index and permanent care home residence at351
baseline, as the explanatory variables which were predicted a priori to be the possible factors352
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affecting both resource use and QALYs in the trial follow-up. Moreover, QALYs were controlled for353
baseline EQ-5D index as recommended for trial-based cost-utility analysis, [32] age and care home354
residence were found to be the predictors of missing QALYs values (see Appendix S4), and block355
randomization was stratified for previous residence in a care home, which justified inclusion of these356
covariates in the adjustment models. Additionally, one year pre-admission healthcare cost was357
expected to be a strong predictor of trial resource use and costs. Baseline Barthel ADL, NPI, and358
number of medical conditions were included as the potential predictors of physical and mental359
health state at follow-up, and so QALYs were adjusted for these covariates. Baseline patient360
characteristics by trial arm, included in the adjusted CEA, are reported in Appendix S5.361
362
Regression techniques, employing a generalised linear model (GLM), were applied to adjust costs363
and QALYs by baseline characteristics. The appropriate distributional family type for the variance364
function was chosen by using the modified Park test; [33] Pregibon link and modified Hosmer-365
Lemeshow tests were used to diagnose any misspecification of the link function. [21] Regression366
models and diagnostic tests were calculated on each imputed dataset, to obtain adjusted cost and367
QALYs averaged across 100 imputations (Rubin’s rules), and to find the optimal GLMs for both costs368
and QALYs (considering the worst test results across imputations). Gamma distribution family and369
log link were chosen for costs, and normal family distribution and power link 0.25 were chosen for370
QALYs. [28] Adjusted patient cost and QALYs, calculated using the recycled prediction method, [21]371
were used to generate cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs)372
on each imputed dataset; the full sample CEAC was obtained from the probability of cost-373
effectiveness for a given ceiling ratio, averaged across 100 imputations.374
375
376
Complete-case cost-effectiveness analysis (alternative approach)377
378
In the complete-case CEA, comprising 209/599 (34.9%) patients with complete QALY and trial cost379
data, for whom one year pre-admission secondary care cost data were also complete, unadjusted380
costs in MMHU and standard care were analysed, handling uncertainty by non-parametric381
bootstrapping. [31]382
383
Adjusted cost was estimated controlling for age, sex, utility and permanent care home residence at384
baseline, and one year pre-admission secondary and tertiary care cost (pre-admission primary care385
costs are omitted here). Adjusted QALYs were estimated controlling for age, sex, and baseline utility,386
permanent care home residence, number of medical conditions, delirium at admission (defined by a387
score of at least 18/46 on the delirium rating scale (DRS-R-98 [34])) and severe cognitive impairment388
(Mini-Mental State Examination (MMSE) [35], MMSE ≤ 9). The reasons for inclusion of these baseline 389
characteristics in the adjustment models were similar to the full-sample cost-effectiveness analysis.390
However, only covariates with complete data in the sub-sample of 209 patients were considered for391
the models for adjusted cost and QALYs. In particular, one year pre-admission secondary and tertiary392
care cost, permanent care home residence, and number of medical conditions were included as393
covariates in the models. To control QALYs for mental health status at baseline, DRS and MMSE394
variables were used, for which data for 2 and 1 participants, respectively, were missing in the395
complete-case CEA sub-sample (patients with missing DRS and MMSE baseline values were assumed396
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to have delirium and severe cognitive impairment at admission). Baseline patient characteristics by397
trial arm, included in the adjusted complete-case CEA, are reported in Appendix S5.398
399
A diagnostic process was used to find the optimal GLMs for both costs and QALYs (the same tests as400
for the full-sample analysis). Gamma distribution family and power link 0.95 were chosen for costs,401
normal distribution family and power link 0.6 were chosen for QALYs. Recycled prediction method to402
generate adjusted patient cost and QALY was applied.[21]403
404
405
Results406
407
Intervention cost408
409
Per-bed-day MMHU additional cost was £25. In the full sample, mean length of stay on MMHU was410
15 days (95% confidence interval [CI]: 13, 16), and the mean per-patient cost of delivering the411
intervention (mean per-patient MMHU additional cost) was £368 (95% CI: 334, 410) – calculations are412
presented in Table 1.413
414
415
Full-sample (using imputed data) cost-effectiveness analysis416
417
In the full-sample cost-effectiveness analysis (CEA), 599 (MMHU: 309) participants were analysed at418
90-day follow-up, at which point 139 (MMHU: 68) were dead. In the unadjusted analysis, comparing419
the MMHU to standard care, the cost of inpatient care was non-significantly lower (-£434, 95% CI: -420
1199, 357), social care cost was non-significantly lower (-£194, 95% CI: -657, 301), and the cost of421
care (primary, secondary, tertiary and social care) was non-significantly lower (-£690, 95% CI: -1571,422
246), resulting in incremental total cost of -£322 (95% CI: -1219, 621). The difference in QALYs423
gained was non-significant (0.008, 95% CI: -0.005, 0.020). In the adjusted CEA, the total cost for the424
MMHU was lower by -£149 (95% CI: -298, 4), with QALYs gained difference equal to 0.001 (95% CI: -425
0.006, 0.008), and a 58% probability of the MMHU being dominant (cost-saving with QALY benefit)426
and a 94% probability of cost-effectiveness (at a £20,000/QALY threshold). The probability of the427
MMHU being cost-saving with QALY loss (SW quadrant) was 39% (Tables 2 and 3, Figures 1 and 2).428
429
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Table 2. Full-sample cost-effectiveness analysis (mean cost in £ / mean QALYs, 95% CI)
MMHU
(309 patients)
Standard carea
(290 patients)
Incremental cost / QALYs gained
The cost of carebc 7266 (6707, 7861) 7956 (7307, 8681) -690 (-1571, 246)
The cost of care – adjustedd 7345 (7248, 7441) 7862 (7758, 7965) -517 (-660, -374)
Additional MMHU cost 368 (334, 410) 0 368 (334, 410)
Total cost
(care cost + MMHU cost)
7634 (7062, 8253) 7956 (7307, 8681) -322 (-1219, 621)
Total cost - adjusted
(care cost adjusted + MMHU cost)
7714 (7606, 7822) 7862 (7758, 7965) -149 (-298, 4)
QALYs gainedb 0.111 (0.101, 0.121) 0.103 (0.093, 0.114) 0.008 (-0.005, 0.020)
QALYs gained – adjustede 0.109 (0.102, 0.116) 0.108 (0.101, 0.114) 0.001 (-0.006, 0.008)
ICER MMHU dominant
ICER adjusted MMHU dominant
aGeriatric ward (204 patients) and general ward (86 patients).
bPrimary care cost and QALY imputed using Multiple imputation by chained equation (MICE). Multiple imputation model applying
predictive mean matching (pmm) for costs and utilities, and ordered logit (ologit) for Barthel ADL scores, DEMQOL, and NPI; 100
imputations generated.
cHealthcare (inpatient, day-case, outpatient, EMAS, MHT, critical care, primary care) and social care cost.
dAdjusted by age, sex, utility and permanent care home residence at baseline, and one year pre-admission healthcare cost care cost. A
GLM model (family – gamma, link – log) was applied, as it was found to be optimal upon diagnostic procedure on each imputation (the
worst test results across imputations were: Park test for gamma family, p-value=0.05, Pregibon link test, p-value=0.36, Hosmer-
Lemeshow test, p-value=0.11)
eAdjusted by age, sex, and baseline utility, permanent care home residence, number of medical conditions, NPI, and Barthel ADL. A GLM
model (family – normal, link – power 0.25) was applied, as it was found to be optimal upon diagnostic procedure on each imputation
(the worst test results across imputations were: Park test for normal family, p-value=0.02, Pregibon link test, p-value=0.50, Hosmer-
Lemeshow test, p-value=0.07, with Park test p-value being higher than 0.05 for 95% imputations and with average Park test p-value
across imputations equal to 0.41).
430
431
13 | P a g e
Table 3. Full-sample cost analysis (mean cost in £, 95% CI)
MMHU
(309 patients)
Standard carea
(290 patients)
Incremental cost / QALYs gained
Inpatient cost 5185 (4715, 5741) 5619 (5053, 6222) -434 (-1199, 357)
Day-case cost 17 (6, 32) 60 (37, 93) -42 (-77, -15)
Outpatient cost 174 (151, 199) 192 (169, 223) -19 (-57, 16)
Primary care costb 221 (200, 247) 206 (184, 232) 16 (-21, 47)
Critical care 8 (0, 22) 56 (2, 202) -48 (-185, 10)
Ambulance service (EMAS) 26 (12, 44) 17 (8, 29) 9 (-9, 31)
Mental Health Trust (MHT) 110 (82, 141) 87 (59, 1276) 22 (-25, 65)
Total healthcare cost 5741 (5261, 6298) 6238 (5648, 6908) -496 (-1285, 320)
Social care cost 1525 (1236, 1830) 1718 (1363, 2126) -194 (-657, 301)
The cost of carec 7266 (6707, 7861) 7956 (7307, 8681) -690 (-1571, 246)
NB: the cost of the intervention is not included in these cost estimates. The cost of the intervention is presented in Table 2.432
aGeriatric ward (204 patients) and general ward (86 patients).433
bPrimary care cost imputed using Multiple imputation by chained equation (MICE). Multiple imputation model applying predictive mean434
matching (pmm); 100 imputations generated.435
436
437
Figure 1. Cost-effectiveness plane – pairwise bootstrapping (adjusted analysis, full-sample438
imputed analysis). Bootstrapped incremental costs and QALYs were obtained for each imputation439
(5000 replications), and these were used in the full-sample cost-effectiveness analysis.440
Consequently, a cost-effectiveness plane should be drawn for 100 imputations (which would be441
impossible to present (100 ∙ 5000 = 500 000 points)). Hence, to approximate and illustrate the cost-442
effectiveness plane for the full-sample imputed analysis, 100 replications randomly chosen from443
each imputation were plotted in this figure (100 ∙ 100 = 10 000 points). The red square represents 444
the point estimate: 0.001 QALY and -£149.445
446
Figure 2. Cost-effectiveness acceptability curves (adjusted analyses) – full sample and complete-447
case analyses. Full-sample cost-effectiveness acceptability curve is obtained from probability of cost-448
effectiveness for given ceiling ratio, averaged across 100 imputations. CEACs represent probability of449
cost-effectiveness of MMHU for given WTP, where WTA is assumed to be equal to WTP (SW450
quadrant of cost-effectiveness plane, see Figures 1 and 3).451
452
453
Probability of cost-effectiveness for £20,000 WTP threshold in relation to WTA/WTP ratio is454
presented in Figure 3 (full-sample). It is shown that this probability goes down from 94% (WTA/WTP455
ratio equal to 1, as assumed in Figure 2 for the full-sample CEAC) to 86% for the ratio equal to 2, to456
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73% for the ratio equal to 5, approaching 59% for the infinite ratio (infinite WTA threshold -457
interpreted as non-acceptance of QALY loss for any amount of money saved).458
459
Figure 3. Probability of cost-effectiveness for WTP threshold equal to £20,000 in relation to460
WTA/WTP ratio – full sample and complete-case analyses.461
462
463
Complete-case cost-effectiveness analysis464
465
In the subgroup of 209 (MMHU: 109) patients with complete QALY and resource-use data, including466
49 (MMHU: 24) patients dead at follow up, comparing MMHU to standard care, the total cost was467
non-significantly lower (-£402, 95% CI: -2227, 1297) and the difference in QALYs gained was non-468
significant (0.007, 95% CI: -0.013, 0.027). In the adjusted CEA, the total cost for MMHU was lower (-469
£206, 95% CI: -591, 153) with no QALYs gained difference (0.000, 95% CI: -0.011, 0.011) and a 47%470
probability of the MMHU being dominant, and a 81% probability of cost-effectiveness (at a471
£20,000/QALY threshold). The probability of the MMHU being cost-saving with QALY loss (SW472
quadrant) was 40%. (Table 4, Figures 2 and 4)473
474
Table 4. Complete-case cost-effectiveness analysis (mean cost in £ / mean QALYs, 95% CI)
MMHU
(109 patients)
Standard carea
(100 patients) Incremental cost / QALYs gained
The cost of careb 7430 (6399, 8631) 8203 (7052, 9751) -772 (-2440, 942)
The cost of care – adjustedc 7553 (7311, 7807) 8130 (7888, 8385) -577 (-833, -335)
Additional MMHU cost 371 (309, 440) 0 371 (309, 440)
Total cost
(care cost + MMHU cost) 7801 (6720, 9031) 8203 (7052, 9751) -402 (-2227, 1297)
Total cost - adjusted
(care cost adjusted + MMHU cost) 7924 (7654, 8197) 8130 (7888, 8385) -206 (-591, 153)
QALYs gained 0.123 (0.109, 0.137) 0.116 (0.102, 0.130) 0.007 (-0.013, 0.027)
QALYs gained – adjustedd 0.120 (0.112, 0.128) 0.120 (0.112, 0.127) 0.000 (-0.011, 0.011)
ICER MMHU dominant
ICER adjusted MMHU dominant
aGeriatric ward (66 patients) and general ward (34 patients).
bInpatient, day-case, ambulance service (EMAS), Mental Health Trust (MHT), critical care, outpatient, primary care, and social care.
cAdjusted by age, sex, utility and permanent care home residence at baseline, and one year pre-admission secondary care cost. A GLM model
(family - gamma, power link - 0.95) was applied. Park test for gamma family, p-value=0.92, Pregibon link test, p-value=0.39, Hosmer-Lemeshow
test, p-value=0.36.
dAdjusted by age, sex, and baseline utility, permanent care home residence, number of medical conditions, delirium (DRS-R-98 > 17.75) and
severe cognitive impairment (MMSE ≤ 9). A GLM model (family - normal, power link - 0.6) was applied. Park test for normal family,                    p-
value=0.07, Pregibon link test, p-value=0.68, Hosmer-Lemeshow test, p-value=0.20.
475
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Figure 4. Cost-effectiveness plane – pairwise bootstrapping (adjusted analysis, complete case476
analysis). Red square represents point estimate 0.000 QALY and -£206.477
478
479
Probability of cost-effectiveness for £20,000 WTP threshold in relation to WTA/WTP ratio is480
presented in Figure 3 (complete-case). This probability goes down from 81% (WTA/WTP ratio equal481
to 1, as assumed in Figure 2 for the complete-case CEAC) to 74% for ratio equal to 2, to 63% for ratio482
equal to 5, approaching 48% for infinite ratio (infinite WTA threshold). (Figure 3)483
484
485
Discussion486
487
Summary of results488
489
The specialist unit for people with delirium and dementia did not demonstrate convincing benefits in490
health status over usual hospital care, as no significant effect on QALY gain was observed. However,491
the results did show a trend towards cost savings and a high probability of cost-effectiveness (94%)492
from a combined health and social care perspective, when usual criteria were applied. When493
excluding the cases in which there were cost savings but worse outcomes (QALY loss), the494
probability of cost-effectiveness fell to 59%.495
496
497
Internal validity498
499
The strengths of this study were that it was conducted as part of a RCT rather than a less robust500
design, resource-use ascertainment was by extraction from electronic datasets rather than recall501
enhancing the quality of the data and hence results, and multiple resource-use datasets were502
examined to produce a more comprehensive estimate of costs than using a single and potentially503
unreliable data source. The economic evaluation was conducted independently of the clinical service504
and, in large part, independently of the investigators who had designed and implemented the505
clinical effectiveness evaluation.506
507
There were considerable missing data, due to the inability of frail and cognitively impaired508
participants to complete EQ-5D, and a systematic difference in values for proxy compared with self-509
completed EQ-5D. Hence imputation was used, incorporating proxy EQ-5D and other clinical510
measures, to estimate the true impact of MMHU care on patients’ health status, which could be a511
source of error. Employing an alternative approach omitting missing data (complete-case analysis)512
showed no major differences in results; however, we did not ascertain informal care or privately513
funded costs, meaning that our findings are limited to the health and social care service perspective.514
Informal care costs form an important part of total costs for people with dementia. [36] The findings515
represent a comparison between the MMHU and standard care. However, 70% of standard care was516
situated on specialist acute geriatric medical wards delivering comprehensive geriatric assessment,517
which is known to deliver better health outcomes than general internal medical wards for frail older518
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people (that is, an ‘active control’). [37] The impact of the MMHU on health status may therefore519
have been understated compared with less specialist care.520
521
The EQ-5D has limitations as a preference-based generic health status measure for calculating QALYs522
in frail and cognitively impaired older people with progressive conditions. Firstly, the EQ-5D is a523
simple, five dimension, 3-level measure of health status which may be insensitive to changes in524
health that are important in this context. [38 39] There is some evidence to support the EQ-5D as a525
valid measure for assessing quality of life in older people, [40] including people with cognitive526
impairment using proxies when necessary. [41] Due to the advocacy by NICE to use the EQ-5D for527
comparability between studies, and the lack of other, more sensitive preference-based measures528
which can be used to elicit the QALY, the EQ-5D was the best preferred option for performing this529
economic evaluation. At the time of planning this study the DEMQOL, a condition specific quality of530
life measure for use in older people with dementia, [42] did not have a valid preference-based531
scoring tariff. The DEMQOL may be more sensitive for measuring condition-specific quality of life but532
was no different when measured in survivors at the end of the follow up period. [8] More recently533
the UDEMQOL has been developed as a preference-based version of the DEMQOL which can be534
used as a condition-specific preference-based measure for eliciting the QALY. [43 44] The UDEMQOL535
can be used to provide complimentary results for comparison with the EQ-5D [13 44] and should be536
considered for use in future studies if further studies establish its validity in this setting. [44]537
Secondly, the QALY as elicited by the EQ-5D is a unidimensional metric of change in health status538
over years of life, and therefore does capture broader aspects of well-being, [45 46] capability [47-539
50] or the ‘spillover’ effect on carers [51 52] that may have been affected by the intervention. These540
aspects are increasingly recognised as areas that should be accounted for when assessing the541
economic outcome of trials. [13 48 52] Evidence from the TEAM trial showed that participants on542
the MMHU spent significantly more time with positive mood or engagement, and experienced more543
staff interactions that addressed emotional and psychological needs. [8] Additionally, more family544
carers in MMHU arm were satisfied with care. For these reasons, we believe our analysis only545
presents a partial assessment of the overall benefit of the intervention.546
547
This economic evaluation was derived from trial data up to three months of follow-up, without548
measuring or modelling the health and cost outcomes beyond this horizon. However, given the fast549
moving changes in clinical conditions of patients, the health and cost effects of MMHU care are likely550
to be limited to a short period after hospital stay, and the trial follow-up was long enough to assess551
effects of the MMHU (cf. trial protocol [7] and [8]), although the trends towards cost savings (such as552
from long term care) may have been stronger if we had data from a longer period of follow up.553
554
555
External validity/context556
557
This is the first study of this specific model of care: no cost-effectiveness analyses of specialist unit558
care for cognitively impaired frail older people have been identified. [53] However, the patient group559
involved and the core processes of the MMHU were similar to the patient groups and core processes560
involved in services delivering comprehensive geriatric assessment (CGA), where a potential cost561
reduction compared with general medical care has been observed. [53 54] Thus this study562
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contributes towards, and is compatible with, a small evidence base about the economic563
consequences of CGA.564
565
The economic impact of the health and social care of older people has been rarely described fully.566
[36 55] Despite recommendations to assess opportunity costs [56], only half of published studies567
measured costs other than secondary care, even fewer including long term or social care costs: the568
eight studies reporting costs in CGA trials in a recent review only reported costs from a hospital569
perspective, and so did not investigate whether costs were shifted to other areas of health care, or570
to social care or informal carers. [54] Thus, this study is an important contribution to the evidence571
base, particularly because around 1/3 of the cost savings observed in this study were non-hospital572
costs (social and primary care). Despite the fact that cost savings shown were only small percentages573
of the total care cost occurred in the standard care arm (4% and 2%, for unadjusted and adjusted574
costs, respectively), the potential cost savings for the NHS could be large if similar specialist575
dementia care is implemented in the UK hospitals.576
577
578
What the results mean579
580
The value of these findings depends upon the degree to which the findings from economic studies581
based on trials that were not positive for their primary outcome are judged by those using such582
information, and the degree to which conventional cost-effectiveness estimates are judged when583
they rely considerably upon cases in which there were cost savings but QALY losses. Health care584
funders may find that cost-effectiveness findings based upon QALY gains at additional cost585
(willingness to pay, WTP) are more acceptable than cost savings and QALY losses (willingness to586
accept, WTA) – an issue discussed widely in the health and behavioral economics literature (cf. [24-587
26]). Hence, we provided the sensitivity analysis to incorporate possible WTA/WTP disparity, by588
estimating probability of cost-effectiveness dependent on the value of WTA/WTP ratio. [24] Due to589
unknown decision makers’ preference over WTA/WTP, the interpretation of such sensitivity analysis590
is limited to the extreme in which small QALY loss is not accepted for any level of cost-savings. In this591
study, the interpretation is even more difficult because of the possibility that the overall benefits of592
the intervention may have been understated in the economic analysis. However, we conclude that593
there are sufficient grounds for further development of evaluation of specialist medical and mental594
health units.595
596
The further development and evaluation of this comprehensive model of care can be guided by the597
results of this study. For example, this study illustrates the potential value of determining a wider598
range of health and social costs to appraise the total impact of services. Given that considerable599
effort was put into discharge planning, communication with families and care homes, referral to600
community services, and advance care planning, it is likely that the accumulation of multiple small601
incremental improvements in multiple processes and outcomes can only be observed when multiple602
sources of costs across the health and social care system are taken into account.603
604
Mortality was high in the population studied (25% at 90 days).[8] It is difficult to define measurable605
outcomes in studies of palliative and supportive care, but patient experience and carer satisfaction606
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are likely to be important. The NHS Outcomes framework includes ‘a positive experience of care’ as607
one of its five domains. [57] Tools widely used to measure health care outcomes in economic608
evaluations do not appear to discriminate well in the end-of-life care context, [58] so carer609
preferences should be incorporated in healthcare decision making. [59] Economic evaluation of such610
services may need to consider broader outcomes than the QALY. For example, a recent study has611
shown the advantages of multiple domain comparisons, emphasizing transparency and better612
informing reimbursement and research decisions when using this approach. [60] Therefore,613
considering the totality of outcomes, including patient experience and carer satisfaction (a cost-614
consequences analysis), would emphasize effects that may be more appropriate for frail older615
patients, often approaching the end of life. An alternative would be a cost minimization approach.616
Our findings suggest that care on the specialist unit was preferable (better quality and experience617
even if health status was no different). In this case, costs can be compared to determine preference.618
In this study, we showed a trend towards cost reduction in the MMHU arm, and hence a trend619
towards superiority.620
621
In conclusion, further development and evaluation of specialist units in general hospitals for people622
with dementia and delirium is warranted based on the fact that the unit studied here led to better623
quality of care, [8] has a reasonable probability of cost-effectiveness even when cost saving QALY624
losing cases are not included in the estimate of cost-effectiveness, and showed a trend towards cost-625
savings when a cost minimisation approach is taken. Such units should be seen as an important626
response to the challenge of managing mental health conditions in general hospitals, in addition to627
liaison old age psychiatry services. Further research of similar services should aim to find better ways628
of capturing health benefits in patient groups receiving palliative and supportive care, and use629
multiple cost sources to assess the full cost impact.630
631
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